Additionally, BCMA, a target commonly utilized in CAR-T cell therapies [27, 122, 123], is increasingly being considered for TCR-based strategies due to its prevalent expression in MM cells [124]. Here, TNFRSF17 is linked to Miyoshi myopathy.